Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 9:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2929–2952 of 81,002 matching trials from the live ClinicalTrials.gov search.
Conditions
Prevention of Chemotherapy-induced Myelosuppression
Interventions
ALRN-6924, TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)
Drug
Lead sponsor
Aileron Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
5
States / cities
Tamarac, Florida • Huntersville, North Carolina • Wilson, North Carolina + 2 more
Conditions
Lung Cancer, Metastatic Cancer
Interventions
pemetrexed disodium, radiation therapy
Drug · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Burlington, North Carolina • Chapel Hill, North Carolina
Conditions
Diabetes Mellitus Type 1 and 2, Diabetes Mellitus Complications, Gastroparesis, Gastrointestinal Motility Disorder
Interventions
RM-131, Placebo
Drug
Lead sponsor
Motus Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Diabetes Mellitus Type 2
Interventions
Placebo, aleglitazar
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Chino, California • Los Angeles, California • Santa Ana, California + 20 more
Conditions
Sudden Cardiac Death
Interventions
Arm 1 (ATP+Shock), Arm 2 (shock only)
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
21 Years and older
Enrollment
2,692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
89
States / cities
Huntsville, Alabama • Anchorage, Alaska • Mesa, Arizona + 82 more
Conditions
Chronic Myelogenous Leukemia
Interventions
Gleevec
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Interventions
LMP2A-loaded conventional DC vaccine, DUK-CPG-001
Biological
Lead sponsor
David Rizzieri, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
AC2993, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years to 75 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
126
States / cities
Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 99 more
Conditions
Cancer, Tumor, Advanced Cancer
Interventions
Molecular profile
Genetic
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Conditions
Melanoma (Skin)
Interventions
Interferon alfa, Radiation therapy
Biological · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
2
States / cities
Miami, Florida • Tampa, Florida
Conditions
Psoriasis
Interventions
Ustekinumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Francisco, California
Conditions
Breast Cancer
Interventions
Low AGE diet, Research blood draw
Other · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Acute Myeloid Leukemia
Interventions
GA-directed treatment regimens
Drug
Lead sponsor
University of Rochester
Other
Eligibility
60 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Rochester, New York
Conditions
Coronary Arteriosclerosis, Acute Coronary Syndrome
Interventions
prasugrel 10 mg, clopidogrel, prasugrel placebo, prasugrel 60 mg, clopidogrel placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 74 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
Jacksonville, Florida • Baltimore, Maryland • Worcester, Massachusetts + 6 more
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Stage I Colon Cancer, Stage I Rectal Cancer, Stage II Colon Cancer, Stage II Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer
Interventions
resveratrol, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
Inlexisertib, Trametinib, Binimetinib, Sotorasib
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
10
States / cities
Boston, Massachusetts • St Louis, Missouri • New Brunswick, New Jersey + 7 more
Conditions
Lipoprotein Disorder
Interventions
Kylo-11 or matched placebo
Drug
Lead sponsor
Kylonova (Xiamen) Biopharma co., LTD.
Industry
Eligibility
18 Years to 80 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Los Angeles, California • Oxnard, California • San Diego, California + 15 more
Conditions
Leukemia
Interventions
PR1 leukemia peptide vaccine, sargramostim, placebo
Biological · Other
Lead sponsor
The Vaccine Company
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
15
States / cities
Scottsdale, Arizona • Los Angeles, California • South San Francisco, California + 10 more
Conditions
SARS-CoV-2 (COVID-19) Severe Pneumonia
Interventions
Efzofitimod 1 mg/kg, Efzofitimod 3 mg/kg, Placebo
Drug
Lead sponsor
aTyr Pharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
8
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 5 more
Enrolling by invitation No phase listed Observational

Subscapularis-Sparing Total Shoulder Arthroplasty

NCT07410650
Conditions
Total Shoulder Arthroplasty
Interventions
Subscapularis-Sparing Total Shoulder Arthroplasty
Procedure
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
Interventions
LEE011
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
0 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
5
States / cities
Birmingham, Alabama • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
Conditions
Glioblastoma, Glioblastoma Multiforme
Interventions
EGFR BATs with TMZ following SOC RT/TMZ, Weekly EGFR BATs following SOC RT/TMZ
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Completed Not applicable Interventional Results available

Effectiveness of Peer-Delivered Trauma-Specific Treatment

NCT02081417
Conditions
Post-Traumatic Stress Disorder, Substance Use Disorders
Interventions
Seeking Safety
Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Española, New Mexico
Conditions
Cigarette Smoking, Schizophrenia, Bipolar Disorder, Depressive Disorder, Major, Smoking Cessation
Interventions
Academic Detailing, Community Health Worker, Treatment as Usual (TAU)
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts